- Location
Ipsen
"-
PeptiDream and France-Based Ipsen Have Expanded Their Research Collaboration
Oct 9, 2013Japanese pharmaceutical firm PeptiDream and France-based Ipsen have expanded their research collaboration and license option agreement signed in April 2013 to develop peptide drugs to treat serious endocrinologic disease. The deal has now ...
Tags: PeptiDream, Ipsen, peptide drugs
-
Ipsen's Dysport Has Received Marketing Authorization From Health Canada
Apr 11, 2013Ipsen's Dysport has received marketing authorization from Health Canada for use in aesthetic medicine in the region. A division of Valeant Pharmaceuticals named Medicis Aesthetics Canada will market Dysport in the region. Ipsen's group ...
Tags: Health, aesthetic medicine
-
Teijin Pharma Will Launch Ipsen's Somatuline Subcutaneous Injection
Jan 22, 2013Teijin Pharma will launch Ipsen's Somatuline subcutaneous injection in 60mg, 90mg and 120mg doses, indicated to treat acromegaly and pituitary gigantism, in Japan. The medication is indicated for acromegaly and pituitary gigantism ...
-
Ipsen Selected MHV Survivor Model Pumps for a Vacuum Furnace Application
Jan 16, 2013Ipsen, Inc., manufacturer of vacuum and atmosphere furnaces, recently selected MHV Survivor model pumps for a vacuum furnace application. The Ipsen furnace is designed for heat treating parts at a major commercial heat treating plant ...
Tags: Ipsen, vacuum, atmosphere furnaces, pump
-
Cisco CEO John Chambers Says He May Retire in Two to Four Years
Jan 4, 2013Network World - Cisco CEO John Chambers says he may retire in two to four years and named several executives who could succeed him, according to Bloomberg. There are as many as 10 candidates to assumed leadership of Cisco when Chambers ...
Tags: Cisco, John Chambers, Bloomberg, Retirement
-
The Drug Candidate Is Being Studied to Treat Acquired Hemophilia a Individuals
Dec 14, 2012Ipsen and Inspiration Biopharmaceuticals have announced FDA Fast Track status to an intravenous recombinant porcine factor VIII, OBI-1, for acquired hemophilia A therapy. The drug candidate is being studied to treat acquired hemophilia A ...
Tags: FDA, fast track status, drug candidate
-
Inspiration Biopharmaceuticals Submitted Bla to The FDA
Dec 6, 2012Inspiration Biopharmaceuticals has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the approval of IB1001, used for the treatment and prevention of bleeding in individuals with hemophilia B. ...
Tags: FDA, IB1001, intravenous recombinant factor IX protein
-
Ipsen Avoided an Interruption in US Supply of Increlex to Treat Severe PrimaryIGF-1
Nov 28, 2012Ipsen has avoided an interruption in US supply of Increlex (IGF-1) to treat Severe Primary IGF-1 Deficiency due to delays in manufacturing site approval. Ipsen has worked in close relation with the US Food and Drug Administration to ...
Tags: Ipsen, Increlex Supply, Severe Primary IGF-1 Deficiency
